via Medical Xpress
A recently developed system for switching on the activity of genes could improve treatments for a broad range of neurological diseases. Esteban Engel, a researcher in viral neuroengineering in the Princeton Neuroscience Institute, and his team have developed new “gene promoters” – which act like switches to turn on gene expression – that promise to broaden the ability to deliver large genes and keep them active for long periods of time.
The research was published online this week in the journal Molecular Therapy: Methods & Clinical Development.
The team is developing these genetic switches for use in gene therapy, the practice of delivering new genes to replace or assist those that are faulty. Gene therapy is a promising strategy for many diseases, including disorders that involve the brain, such as Parkinson’s disease and Alzheimer’s disease.
To carry genes into cells, scientists take advantage of the fact that viruses come equipped with the machinery to gain entry to cells. Over the years, scientists have engineered viruses to deliver genes in ways that are safe and don’t cause disease. One of the viruses commonly used for this is the relatively harmless adeno-associated virus (AAV).
Engel and his team created new gene promoters that turn on genes after they have been transported into neurons – the cells of the brain and nervous system. The team designed their promoters by adopting attributes of promoters found in another class of viruses, the herpes viruses, which persist for years in the body by establishing a chronic infection in the nervous system.
The team’s engineered promoters occupy far less space than existing promoters used in gene therapy, allowing the transport of larger genes or multiple genes. The new promoters are also long-lasting, being less prone to repression or inactivation than most common promoters, so the therapeutic genes are active for long periods of time. These new promoters work with AAV as well as other viral and non-viral gene-delivery systems.
“These new promoters will allow us to deliver larger genes or multiple small genes,” Engel said, “and the genes can remain active for as long as they are needed.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- A neurological condition stopped her from running forward. So she turned around
After being diagnosed with focal dystonia, a neurological movement disorder, Justine Galloway couldn't run forward but could enjoy the sport backwards.
- Smith: Maple Hill Farms deer herd depopulated due to chronic wasting disease
GILMAN - The herd of 301 white-tailed deer was eliminated last week at a northern Wisconsin farm where chronic wasting disease had been detected, according to officials with the Department of ...
- Glyphosate Weed Killer Crosses Blood-Brain Barrier, Linked to Alzheimer’s and Other Neurodegenerative Diseases
An Arizona State University (ASU) study shows that the popular herbicide glyphosate can infiltrate the brain through the blood (blood-brain barrier), increasing neurological disease risk. The ...
- Researchers use 3D culture techniques to develop improved therapy for neurological diseases
Florida State University researchers have developed a promising strategy for producing therapeutic particles in stem cells, work that could help patients with neurological diseases such as stroke or ...
- New study implicates somatic mutations in neurological disorders
Analysis of tissue from 131 frozen brains has shed light on the role somatic mutations play in the development of neurological disorders.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript
Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Executive ...
- REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the second quarter ended June 30, 2022, and recent operational highlights.
- New molecular device ‘Retro-Cascorder’ uses CRISPR to track and record gene expression over time
Using CRISPR-Cas integrases to incorporate retron barcodes into a cell’s genome, Retro-Cascorder logs receipts of gene expression.
- “A coordinated regulatory dance”: Levine lab identifies new elements involved in genome organization
The surprising finding of the team is that even when the duplicated genes are located far apart, they seem to show highly coordinated gene activity. This happens as a result of a specific region of ...
- John King, Ardent Records co-founder and veteran music promoter, dead at 78
John King, a co-founder of Memphis’ Ardent Records, a veteran music promoter and radio historian, has died. King’s family confirmed he died Monday morning. He was 78. A charming and ...